stay tuned e, robert blum stay tuned o, robert blum stay tuned , robert blum stay tuned company's ceom. stay tuned >>> shares of cytokinetics 34ru7 plummeting after the drug to treat a.l.s. failed in a late-stage trial >> we know a.l.s. has been a tough area for drug development, a fatal disease with a huge need for better therapies 15,000 people in the u.s. are estimated to have a.l.s. there are only two drugs approved by the fda to treat it. neither can reverse its court. let's bring in robert blum, cytokinetics ceo thanks for joining us on a tough day for your company. >> thank you, good afternoon, meg. this is a providing sad day for a.l.s. community our late-stage study did not meet its goal but even as hard as it is for our company, it's even more sad for those patients suffering from a.l.s. >> we understand that, you know, as a result of these trial results, you're suspending this program. you seem to have some optimism in your next-generation drug can you tell us why? >> yes we do have optimism coming out of this study. we did see in this study pharmacologic activity that does